Newsroom

The Ivy Brain Tumor Center at Barrow Neurological Institute is pleased to announce the addition of Wonsuk Yoo, PhD, as associate professor of biostatistics. Dr. Yoo’s expertise in preclinical and clinical trial design will be critical in evaluating new treatment modalities for brain tumor patients.

The Ivy Center has appointed Shwetal Mehta, Ph.D., as its chief operating officer. Dr. Mehta is a nationally recognized molecular neuro-oncologist who has distinguished herself as a rising star in brain tumor biology. 

Ivy Brain Tumor Center has announced a new partnership with Vivace Therapeutics. This collaboration will allow researchers at the Ivy Center to evaluate a first-in-class TEAD inhibitor in glioblastoma and meningioma.

The Ivy Brain Tumor Center announced that the first patient has been dosed in an investigator-initiated Phase 0/2 clinical trial of infigratinib in recurrent high-grade glioma driven by FGFR genetic alterations. Infigratinib is an investigational, orally administered, FGFR1-3 selective tyrosine kinase inhibitor being developed by BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate company QED Therapeutics, Inc.

Dr. Nader Sanai, director of the Ivy Brain Tumor Center, says although the survival rate is low it doesn't mean there isn't hope to beat cancer. "These are populational statistics, they don't describe you or predict your future." He and Youngblood are teaming up to bring awareness to the disease for Glioblastoma Awareness Day. Sanai says a day focusing on brain cancer is important because it hasn't seen the same progress in therapies like breast or prostate cancer.

Chamber Business News highlights the Ivy Brain Tumor Center's resilience in fighting brain tumors despite the pandemic and the importance of Glioblastoma Awareness Day. Observed as a day to honor those who have been impacted by the disease, the initiative also supports efforts to develop better treatment options that will improve patients’ long-term prognosis.

The Arizona Republic shares the story of Ian Youngblood, a 29-year-old nurse from Arizona who received a harrowing diagnosis of glioblastoma while helping fight COVID-19 on the frontlines in NYC. Dr. Nader Sanai weighs in on why these types of tumors are so hard to control and what it will take to move the needle on identifying new, effective treatment options.

Dr. Nader Sanai, director of the Ivy Brain Tumor Center and Ian Youngblood, RN, who was recently diagnosed with a brain tumor, have come together for the second annual Glioblastoma Awareness Day (#GBMDay) on July 22, 2020 to raise national consciousness.

Ian's story has moved the country for his strength and selfless service on the COVID-19 frontlines in NYC. Now, facing a battle of his own, he's turning to Dr. Nader Sanai and his team at the Ivy Brain Tumor Center and Barrow Neurological Institute to help him fight one of the most aggressive forms of brain cancer, glioblastoma.

The Ivy Brain Tumor Center at Barrow Neurological Institute has announced the appointment of Benjamin Cravatt, Ph.D to its Scientific Advisory Board. Dr. Cravatt is a world-renowned chemical biologist with extensive experience in drug discovery and drug development.